U.S., May 1 -- ClinicalTrials.gov registry received information related to the study (NCT06952010) titled 'A Study of XB628 in Participants With Recurrent Advanced or Metastatic Solid Tumors' on April 23.
Brief Summary: This is a phase 1, first-in-human, open-label, dose-escalation study of XB628, a first-in-class bispecific antibody natural killer (NK) cell engager that targets NK group 2 member A (NKG2A), an inhibitory receptor on NK cells, and programmed cell death-ligand 1 (PD-L1).
Study Start Date: May, 2025
Study Type: INTERVENTIONAL
Condition:
Solid Tumor
Advanced Solid Tumor
Metastatic Solid Tumor
Immune Sensitive Tumor
Intervention:
BIOLOGICAL: XB628
Intravenous infusion(s)
Recruitment Status: NOT_YET_RECRUITING
Sponsor: ...